↓ Skip to main content

Dove Medical Press

New therapeutic strategies for the treatment of male lower urinary tract symptoms

Overview of attention for article published in Research and Reports in Urology, April 2016
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
2 X users
facebook
1 Facebook page

Citations

dimensions_citation
8 Dimensions

Readers on

mendeley
49 Mendeley
Title
New therapeutic strategies for the treatment of male lower urinary tract symptoms
Published in
Research and Reports in Urology, April 2016
DOI 10.2147/rru.s63446
Pubmed ID
Authors

Konstantinos Dimitropoulos, Stavros Gravas

Abstract

Male lower urinary tract symptoms (LUTS) are prevalent in the general population, especially in those of advanced age, and are characterized by notable diversity in etiology and presentation, and have been proven to cause various degrees of impairment on quality of life. The prostate has traditionally been regarded as the core cause of male LUTS. As a result, medical treatment aims to provide symptomatic relief and effective management of progression of male LUTS due to benign prostatic enlargement. In this context, α1-blockers, phosphodiesterase-5 inhibitors, and 5α-reductase inhibitors have long been used as monotherapies or in combination treatment to control voiding LUTS. There is accumulating evidence, however, that highlights the role of the bladder in the pathogenesis of male LUTS. Current research interests have shifted to bladder disorders, and medical management is aimed at the bladder. Muscarinic receptor antagonists and the newly approved β3-adrenergic agonist mirabegron aim to alleviate the most bothersome storage LUTS and thus improve quality of life. As voiding and storage LUTS frequently coexist, combination therapeutic strategies with α1-blockers and antimuscarinics or β3-agonists have been introduced to manage symptoms effectively. Anti-inflammatory agents, vitamin D3-receptor analogs, and cannabinoids represent treatment modalities currently under investigation for use in LUTS patients. Furthermore, luteinizing hormone-releasing hormone antagonists, transient receptor-potential channel blockers, purinergic neurotransmission antagonists, Rho-kinase inhibitors, and inhibitors of endothelin-converting enzymes could have therapeutic potential in LUTS management, but still remain in the experimental setting. This article reviews new strategies for the medical treatment of male LUTS, which are dictated by the potential role of the bladder and the risk of benign prostatic hyperplasia progression. Moreover, combination treatments and therapies currently under investigation are also presented.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 49 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 49 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 6 12%
Other 5 10%
Student > Bachelor 5 10%
Student > Master 5 10%
Student > Postgraduate 3 6%
Other 7 14%
Unknown 18 37%
Readers by discipline Count As %
Medicine and Dentistry 13 27%
Nursing and Health Professions 6 12%
Pharmacology, Toxicology and Pharmaceutical Science 2 4%
Biochemistry, Genetics and Molecular Biology 1 2%
Economics, Econometrics and Finance 1 2%
Other 3 6%
Unknown 23 47%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 May 2016.
All research outputs
#15,043,267
of 25,576,275 outputs
Outputs from Research and Reports in Urology
#117
of 261 outputs
Outputs of similar age
#155,010
of 315,173 outputs
Outputs of similar age from Research and Reports in Urology
#3
of 3 outputs
Altmetric has tracked 25,576,275 research outputs across all sources so far. This one is in the 40th percentile – i.e., 40% of other outputs scored the same or lower than it.
So far Altmetric has tracked 261 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.7. This one has gotten more attention than average, scoring higher than 55% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 315,173 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 49th percentile – i.e., 49% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one.